Pemphigus vulgaris (PV) is a potentially fatal autoimmune disease of skin adhesion associated with autoantibodies against a number of keratinocyte antigens.1 It is more prevalent in elderly patients, and the lesions typically occur on the scalp, face, neck, and oral cavity (about 90% of patients have oromucosal involvement). The mainstay treatment is with systemic glucocorticoids, which significantly reduced the mortality rate associated with PV compared with no treatment in the presteroid era2 when it was extremely high, ranging from 60% to 90%.